UNSPSC 51401548: Reclazepam

This classification denotes an anxiolytic with the molecular formula C18H13Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJL42911RA, chemically known as 4(5h)-oxazolone, 2-(7-chloro-5-(2-chlorophenyl)-2,3-dihydro-1h-1,4-benzodiazepin-1-yl)-; but generally known as reclazepam, which bears US NIH Compound Identifier 3052777. European Medicines Agency schedules Reclazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10269MIG.

UNSPSC 51401548 Reclazepam is a Commodity code that in practice does not align with recent state and local procurement activity. The single identifiable opportunity posted under this code—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems—solicits opioid-reversal agents and harm-reduction equipment unrelated to reclazepam, a benzodiazepine anxiolytic. The mismatch suggests either a classification error in the posting or a misalignment between the code's pharmaceutical scope and the category's actual use in state and local procurement systems.

Seminole County's June 2026 posting (due July 26, 2026) called for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford and pricing on a fixed-fee basis. The procurement required E-Verify compliance, drug-free workplace certification, and standard commercial insurance; contractors faced a three-month probationary termination window. Beyond this single Florida opportunity, the source provides no additional state or local contracting activity under the code. The scarcity of indexing under UNSPSC 51401548 and the categorical misalignment of the one visible opportunity signal minimal recent procurement traction for reclazepam itself within state and local jurisdictions.